Graybug Vision, Inc.
Graybug Vision, Inc., a pioneering name in the ophthalmic industry, is headquartered in the United States. Founded in 2016, the company focuses on developing innovative therapies for retinal diseases, aiming to transform the treatment landscape for patients suffering from conditions such as age-related macular degeneration and diabetic retinopathy. With a commitment to advancing ocular drug delivery systems, Graybug Vision has made significant strides with its proprietary technologies, including sustained-release formulations that enhance patient compliance and treatment efficacy. The company has garnered attention for its unique approach to drug delivery, positioning itself as a leader in the field. As it continues to expand its operational reach, Graybug Vision remains dedicated to improving vision health and achieving notable milestones in the biopharmaceutical sector.
DitchCarbon Score
How does Graybug Vision, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Graybug Vision, Inc.'s score of 33 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Graybug Vision, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to reducing its carbon footprint at this time. It is important to note that emissions data may be cascaded from related entities. In this case, Graybug Vision, Inc. is a merged entity that inherits performance data from CalciMedica, Inc. However, no specific emissions figures or reduction initiatives have been provided from this source. As the company continues to develop its sustainability strategy, it may consider adopting industry-standard climate commitments and reduction targets to align with global efforts in combating climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 3,140 | 0,000 | 0,000 | 0,000 |
| Scope 2 | 65,610 | 00,000 | 00,000 | 00,000 |
| Scope 3 | 106,660 | 000,000 | 00,000 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Graybug Vision, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
